IL279851A - Preparations and methods for treating diseases or conditions related to inflammasome - Google Patents
Preparations and methods for treating diseases or conditions related to inflammasomeInfo
- Publication number
- IL279851A IL279851A IL279851A IL27985120A IL279851A IL 279851 A IL279851 A IL 279851A IL 279851 A IL279851 A IL 279851A IL 27985120 A IL27985120 A IL 27985120A IL 279851 A IL279851 A IL 279851A
- Authority
- IL
- Israel
- Prior art keywords
- compositions
- conditions
- methods
- related diseases
- inflammasome related
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16/026,482 US10703811B2 (en) | 2016-12-29 | 2018-07-03 | Methods and compositions for treating multiple sclerosis |
| PCT/US2019/040635 WO2020010273A1 (en) | 2018-07-03 | 2019-07-03 | Compositions and methods for treating inflammasome related diseases or conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL279851A true IL279851A (en) | 2021-03-01 |
Family
ID=78823964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL279851A IL279851A (en) | 2018-07-03 | 2020-12-30 | Preparations and methods for treating diseases or conditions related to inflammasome |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US12570735B2 (enExample) |
| EP (1) | EP3818081A4 (enExample) |
| JP (2) | JP7824030B2 (enExample) |
| KR (1) | KR20210071944A (enExample) |
| CN (1) | CN113316588B (enExample) |
| AU (1) | AU2019297515B2 (enExample) |
| BR (1) | BR112020026798A2 (enExample) |
| CA (1) | CA3105129A1 (enExample) |
| CL (1) | CL2020003447A1 (enExample) |
| CO (1) | CO2021001172A2 (enExample) |
| IL (1) | IL279851A (enExample) |
| MX (1) | MX2021000142A (enExample) |
| PH (1) | PH12020552286A1 (enExample) |
| SG (1) | SG11202013176VA (enExample) |
| WO (1) | WO2020010273A1 (enExample) |
| ZA (2) | ZA202100703B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240060995A1 (en) * | 2012-02-06 | 2024-02-22 | University Of Miami | Innate immune proteins as biomarkers for traumatic brain injury in adult and pediatric patients |
| WO2018126009A1 (en) | 2016-12-29 | 2018-07-05 | University Of Miami | Method for modulating inflammasome activity and inflammation in the lung |
| US11840565B2 (en) | 2016-12-29 | 2023-12-12 | University Of Miami | Methods and compositions for treating virus-associated inflammation |
| EP3818081A4 (en) | 2018-07-03 | 2022-06-22 | University of Miami | COMPOSITIONS AND METHODS FOR TREATING INFLAMMASOME-RELATED DISEASES OR DISORDERS |
| US20230296626A1 (en) * | 2020-04-27 | 2023-09-21 | University Of Miami | Compositions and methods for treating inflammasome related diseases or conditions |
| EP4433167A1 (en) * | 2021-11-16 | 2024-09-25 | AC Immune SA | Novel molecules for therapy and diagnosis |
| EP4583974A1 (en) * | 2022-09-09 | 2025-07-16 | University of Miami | Inflammasome antibody compositon and method for treating neurologic disorder |
| WO2024114906A1 (en) * | 2022-11-30 | 2024-06-06 | Mabylon Ag | Antibodies against apoptosis-associated speck-like protein containing a card (asc) and uses thereof |
| WO2026042013A1 (en) * | 2024-08-19 | 2026-02-26 | Institute Of Molecular And Clinical Ophthalmology Basel (Iob) | Mitochondrial therapy |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2763849B1 (fr) | 1997-05-28 | 2000-09-15 | Rhone Poulenc Rorer Sa | Utilisation des heparines de bas poids moleculaire pour la prevention et le traitement des oedemes cerebraux |
| US20040018194A1 (en) | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
| US7244764B2 (en) | 2003-06-23 | 2007-07-17 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| RU2407752C2 (ru) | 2004-04-29 | 2010-12-27 | Оцука Фармасьютикал Ко., Лтд. | Антитела к гликопротеину vi и способы продуцирования и использования этих антител |
| WO2005111283A1 (ja) * | 2004-05-17 | 2005-11-24 | Denki Kagaku Kogyo Kabushiki Kaisha | ポリ塩化ビニル繊維及びその製造方法並びに人工毛髪 |
| KR20070094890A (ko) | 2004-10-25 | 2007-09-27 | 머크 앤드 캄파니 인코포레이티드 | 안티 ａｄｄｌ 항체 및 그 용도 |
| TW200636064A (en) | 2004-10-28 | 2006-10-16 | Centocor Inc | Anti-respiratory syncytial virus antibodies, antigens and uses thereof |
| JP2009510105A (ja) | 2005-09-28 | 2009-03-12 | バイオバスキュラー インコーポレーティッド | 血小板および細胞の接着、細胞移動、および炎症を阻止するための方法および組成物 |
| SI3219328T1 (sl) | 2005-12-29 | 2020-10-30 | Janssen Biotech, Inc. | Človeška protitelesa proti-IL-23, sestavki, postopki in uporabe |
| AU2007267561B2 (en) | 2006-05-25 | 2012-05-17 | Momenta Pharmaceuticals, Inc. | Low molecular weight heparin composition and uses thereof |
| KR20100014588A (ko) | 2007-02-27 | 2010-02-10 | 제넨테크, 인크. | 길항제 ｏｘ40 항체 및 염증성 및 자가면역 질환의 치료에서의 이의 용도 |
| US8685400B2 (en) | 2007-07-30 | 2014-04-01 | University Of Miami | Modulating inflammasome activity and inflammation in the central nervous system |
| EP2300000A1 (en) * | 2008-07-03 | 2011-03-30 | University of Massachusetts | Methods and compositions for reducing inflammation and treating inflammatory disorders |
| EP2145624A1 (en) | 2008-07-18 | 2010-01-20 | Sanofi-Aventis | Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatment |
| WO2011029931A1 (en) | 2009-09-11 | 2011-03-17 | Protaffin Biotechnologie Ag | Composition for treatment of cxcl8-mediated lung inflammation |
| US8759302B2 (en) | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| SMT202000095T1 (it) * | 2010-05-14 | 2020-03-13 | Amgen Inc | Formulazioni di anticorpi anti-sclerostina ad alta concentrazione |
| IT1406201B1 (it) | 2010-12-10 | 2014-02-14 | Univ Degli Studi Trieste | Biomarcatori per la diagnosi della sclerosi multipla |
| ES2578477T3 (es) | 2011-03-11 | 2016-07-27 | Roche Diagniostics Gmbh | ASC como marcador de la enfermedad pulmonar obstructiva crónica (EPOC) |
| WO2013049278A1 (en) | 2011-09-30 | 2013-04-04 | Novartis Ag | USE OF IL-1 ß BINDING ANTIBODIES |
| WO2013119673A1 (en) | 2012-02-06 | 2013-08-15 | University Of Miami | Innate immune proteins as biomarkers for cns injury |
| TWI480044B (zh) | 2012-03-16 | 2015-04-11 | Taichung Veterans General Hospital | A high molecular weight heparin or low molecular weight heparin for the preparation of a composition for at least two consecutive days of administration to improve the allergic constitution |
| US20140314746A1 (en) * | 2013-03-13 | 2014-10-23 | Philadelphia Health And Education Corporation, d/b/a Drexel University College of Medicine | Methods for treating or preventing fibrosis in subjects afflicted with scleroderma |
| MX2015015784A (es) | 2013-05-17 | 2016-03-11 | Genentech Inc | Metodos para diagnosticar y tratar enfermedad inflamatoria de intestino. |
| JP6359013B2 (ja) * | 2013-07-29 | 2018-07-18 | 国立大学法人 鹿児島大学 | １，５−ｄ−アンヒドロフルクトースを含むアポトーシス関連スペック様カード蛋白質の機能阻害薬 |
| JP7066321B2 (ja) | 2014-01-10 | 2022-05-13 | アヴァリン ファーマ インク． | エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用 |
| US10261098B2 (en) | 2014-08-18 | 2019-04-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Biomarkers for diagnosis and management of neuro-immunological diseases |
| CA2964315A1 (en) | 2014-10-16 | 2016-04-21 | Novartis Ag | Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis |
| US20160263183A1 (en) | 2015-03-10 | 2016-09-15 | Brown University | Methods for treating lung disease |
| CN114181281A (zh) | 2015-05-12 | 2022-03-15 | 加利福尼亚大学董事会 | 用于炎症和纤维化的肽治疗 |
| JP6887987B2 (ja) | 2015-08-17 | 2021-06-16 | ティダブリューアイ・バイオテクノロジー・インコーポレイテッドＴＷＩ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． | Ａｓｃの発現、ｎｌｒｐ３の発現、及び／又はｎｌｒｐ３インフラマソーム複合体の形成を阻害するためのジアセレイン又はそのアナログ |
| KR101948048B1 (ko) | 2016-12-08 | 2019-02-14 | 한양대학교 에리카산학협력단 | 톡소포자충 ｇｒａ７ 항원 유래 재조합 단백질을 유효성분으로 포함하는 결핵 예방 또는 치료용 약학 조성물 |
| WO2018126009A1 (en) | 2016-12-29 | 2018-07-05 | University Of Miami | Method for modulating inflammasome activity and inflammation in the lung |
| US11840565B2 (en) | 2016-12-29 | 2023-12-12 | University Of Miami | Methods and compositions for treating virus-associated inflammation |
| US10755739B1 (en) | 2016-12-30 | 2020-08-25 | John Fristrom | Remote railway crossing programmable device and methods thereof |
| CN111356924A (zh) | 2017-09-20 | 2020-06-30 | 迈阿密大学 | 检测作为神经障碍生物标记的炎性体蛋白的方法 |
| EP3818081A4 (en) | 2018-07-03 | 2022-06-22 | University of Miami | COMPOSITIONS AND METHODS FOR TREATING INFLAMMASOME-RELATED DISEASES OR DISORDERS |
-
2019
- 2019-07-03 EP EP19831331.4A patent/EP3818081A4/en active Pending
- 2019-07-03 CN CN201980056542.1A patent/CN113316588B/zh active Active
- 2019-07-03 WO PCT/US2019/040635 patent/WO2020010273A1/en not_active Ceased
- 2019-07-03 US US17/255,653 patent/US12570735B2/en active Active
- 2019-07-03 MX MX2021000142A patent/MX2021000142A/es unknown
- 2019-07-03 SG SG11202013176VA patent/SG11202013176VA/en unknown
- 2019-07-03 JP JP2020573110A patent/JP7824030B2/ja active Active
- 2019-07-03 CA CA3105129A patent/CA3105129A1/en active Pending
- 2019-07-03 AU AU2019297515A patent/AU2019297515B2/en active Active
- 2019-07-03 KR KR1020217003239A patent/KR20210071944A/ko active Pending
- 2019-07-03 BR BR112020026798-8A patent/BR112020026798A2/pt unknown
-
2020
- 2020-12-29 PH PH12020552286A patent/PH12020552286A1/en unknown
- 2020-12-30 CL CL2020003447A patent/CL2020003447A1/es unknown
- 2020-12-30 IL IL279851A patent/IL279851A/en unknown
-
2021
- 2021-02-01 ZA ZA2021/00703A patent/ZA202100703B/en unknown
- 2021-02-02 CO CONC2021/0001172A patent/CO2021001172A2/es unknown
-
2022
- 2022-01-31 ZA ZA2022/01437A patent/ZA202201437B/en unknown
-
2025
- 2025-01-16 JP JP2025006393A patent/JP7850296B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7824030B2 (ja) | 2026-03-04 |
| SG11202013176VA (en) | 2021-01-28 |
| CN113316588A (zh) | 2021-08-27 |
| CA3105129A1 (en) | 2020-01-09 |
| CL2020003447A1 (es) | 2021-07-30 |
| AU2019297515B2 (en) | 2026-06-04 |
| KR20210071944A (ko) | 2021-06-16 |
| JP2025067915A (ja) | 2025-04-24 |
| CN113316588B (zh) | 2025-02-28 |
| CO2021001172A2 (es) | 2021-07-09 |
| JP7850296B2 (ja) | 2026-04-22 |
| MX2021000142A (es) | 2021-05-12 |
| EP3818081A4 (en) | 2022-06-22 |
| ZA202201437B (en) | 2024-05-30 |
| PH12020552286A1 (en) | 2021-06-21 |
| AU2019297515A1 (en) | 2021-02-25 |
| US20210284723A1 (en) | 2021-09-16 |
| WO2020010273A1 (en) | 2020-01-09 |
| US12570735B2 (en) | 2026-03-10 |
| ZA202100703B (en) | 2022-08-31 |
| JP2021528092A (ja) | 2021-10-21 |
| BR112020026798A2 (pt) | 2021-03-30 |
| EP3818081A1 (en) | 2021-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL298690B1 (en) | Preparations and methods for suppressing masp-3 for the treatment of various diseases and conditions | |
| ZA202100703B (en) | Compositions and methods for treating inflammasome related diseases or conditions | |
| IL273959A (en) | Methods and preparations for the treatment of rare diseases | |
| IL274702A (en) | Compounds and Methods for Neurological Diseases | |
| AU2018297285A1 (en) | Compositions and methods for treating or preventing endocrine FGF-linked diseases | |
| EP3687524A4 (en) | COMPOSITIONS AND METHODS OF TREATMENT OF OPHTHALMIC DISORDERS | |
| SMT202500382T1 (it) | Composizioni per trattare e/o prevenire malattie da aggregazione proteica | |
| ZA202006234B (en) | Compositions and methods for the treatment of neurological diseases | |
| SG11202102442WA (en) | Methods and compositions for preventing and treating atherosclerosis and related diseases | |
| IL275767A (en) | Compositions and methods for treating metabolic diseases | |
| IL272937A (en) | Preparations and methods for the treatment of diseases involving fibrosis | |
| IL280413A (en) | Bismuth-thiol preparations and wound treatment methods | |
| EP3445376A4 (en) | COMPOSITIONS AND METHODS FOR IMPROVED RESTORATION AND CONSERVATION OF THE INTEGRITY OF TISSUE BARRIERS | |
| SG11202012055PA (en) | Methods and compositions for preventing or treating calciphylaxis | |
| EP3768095A4 (en) | Compositions and methods for treating diarrheal diseases | |
| IL269743A (en) | Methods and preparations for the treatment of disease related to the retina with CCR-3 inhibitor inventions | |
| EP3265103A4 (en) | Compositions and methods for treating ocular diseases | |
| IL261779A (en) | Preparations for the treatment and prevention of hoof and claw disease | |
| EP3672583A4 (en) | COMPOSITIONS AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES | |
| EP3496696A4 (en) | COMPOUNDS AND METHODS FOR TREATING THE DISEASE. | |
| EP3310338A4 (en) | Compositions and methods for treating inflammatory disease or conditions | |
| IL280262A (en) | Compositions and methods for treating cancer | |
| HK40053279A (en) | Compositions and methods for treating nrp2-associated diseases | |
| HK40021297A (en) | Compositions and methods for treating or preventing gut permeability-related disorders | |
| AU2018900992A0 (en) | Compositions and methods for treating respiratory diseases |